Penbraya (meningococcal groups A, C, W, Y conjugate and group B vaccine (recombinant, adsorbed))
- Region
- 🇪🇺 EU
- Active substance
- meningococcal groups A, C, W, Y conjugate and group B vaccine (recombinant, adsorbed)
- Company
- Pfizer Europe MA EEIG
- Status
- Withdrawn
- Therapeutic area
- Meningitis, Meningococcal
- CHMP opinion
- Thu 19 Sep 2024
- EU approval
- Thu 14 Nov 2024
- Application
- EMEA/H/C/006165
- ATC
- J07AH11
- Official record
- www.ema.europa.eu
Indication
Penbraya is indicated for active immunisation of individuals 10 years of age and older to prevent invasive disease caused by Neisseria meningitidis groups A, B, C, W, and Y. The use of this vaccine should be in accordance with official recommendations.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Nimenrix Authorised · Pfizer Europe MA EEIG
Follow Penbraya
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.